Edwards Lifesciences $125 million convertibles talked to yield 3.375-3.875%, up 90-95%

By Sara Rosenberg

New York, May 5 - Edwards Lifesciences Corp.'s $125 million convertible senior debentures due 2033, scheduled to price Tuesday morning before market open, are talked to yield 3.375% to 3.875% with an initial conversion premium of 90% to 95%, according to market sources.

JPMorgan is the lead bank on the deal, which will be sold in a Rule 144A offering.

There is a $25 million greenshoe.

There is hard call protection for five years and there are puts in years five, 10 and 15.

Both the contingent payment and the contingent conversion thresholds are set at 120%.

Approximately $25 million to $40 million of the net proceeds will be used to repurchase shares of outstanding common stock. The remaining net proceeds will be used for general corporate purposes, which may include the purchase of additional shares of common stock and the repayment of indebtedness.

Edwards Lifesciences is an Irvine, Calif. produces products and services to treat late-stage cardiovascular disease.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.